NASDAQ:BIOC Biocept (BIOC) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.43▼$1.6752-Week Range N/AVolume751,400 shsAverage Volume764,067 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biocept alerts: Email Address Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Biocept Stock (NASDAQ:BIOC)Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.Read More Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. BIOC Stock News HeadlinesMay 24, 2024 | msn.comFoundation Gives $2M to Set Up Margaret Faye Wilson Endowment at Salk InstituteMay 23, 2024 | msn.comWicklow Foundation Gives $2 Million to Establish Margaret Faye Wilson Endowment at Salk InstituteSeptember 8, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 8, 2024 | finanznachrichten.deLiquid Biopsy Market Worth $11.3 billion | MarketsandMarkets.May 2, 2024 | msn.comAkron residents could see water and sewer rate increases over federally mandated projectsMarch 6, 2024 | finanznachrichten.dePlus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsFebruary 27, 2024 | bizjournals.comCircular Genomics brings on 2 leadership hires following $8.3M raiseFebruary 26, 2024 | finance.yahoo.comCircular Genomics Strengthens Leadership Team with Key Commercial and Research HiresSeptember 8, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.December 29, 2023 | fool.comBiocept (NASDAQ: BIOC)November 22, 2023 | msn.comPlus Therapeutics files to sell ordinary shares, warrantsNovember 10, 2023 | finance.yahoo.comBiocept, Inc. (BIOCQ) Stock Historical Prices & Data - Yahoo FinanceNovember 7, 2023 | benzinga.comGenomic Cancer Testing is projected to Hit $45.92 Billion, Globally, by 2030 at 16.1% CAGR: Coherent Market InsightsOctober 18, 2023 | sg.finance.yahoo.comBiocept, Inc. (BIOC) stock price, news, quote & history – Yahoo FinanceOctober 16, 2023 | marketwatch.comBiocept Falls 46% After Chapter 7 FilingOctober 16, 2023 | benzinga.comWhy Is Liquid Biopsy Firm Biocept Stock Trading Lower Today?September 22, 2023 | markets.businessinsider.comMaxim Group Remains a Hold on Biocept (BIOC)September 21, 2023 | finance.yahoo.comEnrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesSee More Headlines Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today9/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNASDAQ:BIOC CUSIPN/A CIK1044378 Webwww.biocept.com Phone(858) 320-8200Fax858-320-8225Employees50Year Founded1993Profitability EPS (Most Recent Fiscal Year)($58.4549) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,090,000.00 Net MarginsN/A Pretax Margin-564.02% Return on Equity-468.87% Return on Assets-118.41% Debt Debt-to-Equity Ratio2.88 Current Ratio1.81 Quick Ratio1.70 Sales & Book Value Annual Sales$25.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$15.60 per share Price / BookN/AMiscellaneous Outstanding Shares2,630,000Free Float2,584,000Market Cap$1.14 million OptionableNot Optionable Beta0.69 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Darrell Taylor Esq. (Age 58)Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Registered In-House Counsel Comp: $432.27kDr. Soon Kap Hahn Ph.D.FounderMr. Rob WalshVP & ControllerDr. Philippe J. Marchand Ph.D. (Age 60)Chief Operating Officer Mr. Pavel TsinbergDirector of Technology DevelopmentMr. David S. Moskowitz R.Ph.MBA, Vice President of Strategy & Corporate CommunicationsDr. Veena M. Singh (Age 48)Senior Medical Director Comp: $361.03kMore ExecutivesKey CompetitorsbioAffinity TechnologiesNASDAQ:BIAFWPrenetics GlobalNASDAQ:PRENWSeqLLNASDAQ:SQLLWStar EquityNASDAQ:STRRPOpGenNASDAQ:OPGNView All Competitors BIOC Stock Analysis - Frequently Asked Questions How were Biocept's earnings last quarter? Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to analysts' expectations of $16.87 million. When did Biocept's stock split? Shares of Biocept reverse split on Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Michael Nall's approval rating as Biocept's CEO? 4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Onconova Therapeutics (ONTX). This page (NASDAQ:BIOC) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredExposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocept, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biocept With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.